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Abstract
Two megalencephaly (MEG) syndromes, megalencephaly-capillary malformation (MCAP) and megalencephaly-polymicro-
gyriapolydactyly-hydrocephalus (MPPH), have recently been defined on the basis of physical and neuroimaging features.
Subsequently, exome sequencing of ten MEG cases identified de-novo postzygotic mutations in PIK3CA which cause MCAP
and de-novo mutations in AKT and PIK3R2 which cause MPPH. Here we present findings from exome sequencing three
unrelated megalencephaly patients which identified a causal PIK3CA mutation in two cases and a causal PIK3R2 mutation in
the third case. However, our patient with the PIK3R2 mutation which is considered to cause MPPH has a marked bifrontal
band heterotopia which is a feature of MCAP. Furthermore, one of our patients with a PIK3CA mutation lacks syndactyly/
polydactyly which is a characteristic of MCAP. These findings suggest that the overlap between MCAP and MPPH may be
greater than the available studies suggest. In addition, the PIK3CA mutation in one of our patients could not be detected
using standard exome analysis because the mutation was observed at a low frequency consistent with somatic mosaicism.
We have therefore investigated several alternative methods of exome analysis and demonstrate that alteration of the initial
allele frequency spectrum (AFS), used as a prior for variant calling in samtools, had the greatest power to detect variants
with low mutant allele frequencies in our 3 MEG exomes and in simulated data. We therefore recommend non-default
settings of the AFS in combination with stringent quality control when searching for causal mutation(s) that could have low
levels of mutant reads due to post-zygotic mutation.
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Introduction
Megalencephaly syndromes (MEG) have been noted to arise as
sporadic overgrowth disorders and have been associated with
variable additional malformations including cortical dysplasia,
developmental vascular anomalies, distal limb malformations and
variable connective tissue dysplasias [1]. Recent findings led to the
characterisation of two MEG syndromes on the basis of physical
and neuroimaging anomalies [1]. These disorders are:
1. Megalencephaly-capillary malformation syndrome (MCAP),
for which most patients would previously have been classified
as Macrocephaly-capillary malformation syndrome (MCM).
2. Megalencephaly-polymicrogyriapolydactyly-hydrocephalus
syndrome (MPPH), which is closely related to MCAP but
patients lack vascular malformations and syndactyly.
Subsequently, exome sequencing of 10 affected individuals, 8
showing the MCAP phenotype, one with MPPH and one with an
overlapping phenotype, was used to identify de-novo germline and
postzygotic mutations in AKT3, PIK3R2 and PIK3CA which are
responsible for the MCAP and MPPH phenotypes [2]. In this
paper, the authors noted that patchy skin vascular malformations
and asymmetric overgrowth seen in MCAP were consistent with
the presence of postzygotic mosaicism being present in some of the
cases. In the case of syndromes for which mosaic skin defects are a
feature, the concept of a lethal gene surviving by mosaicism was
first suggested in 1987 [3]. Such mutations would lead to early
embryonic death when present in the zygote but mutated cells
could survive if in close proximity to normal cells and the mutation
could arise, for example, as an early somatic mutation. Subse-
quently the Proteus overgrowth syndrome was found to be caused
by a somatic activating mutation in the AKT1 gene proving the
hypothesis of somatic mosaicism [4]. The authors identified tissues
and cell lines from patients with Proteus syndrome as having
admixtures of mutant alleles ranging from 1%–50%.
The analysis of a family trio showing clinical features
overlapping MCAP and MPPH by Riviere et al [2] initially
identified a de-novo mutation in the AKT3 gene and they identified
one other individual with such a mutation establishing this as a
rare cause of megalencephaly. Recognising AKT3 as a major
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downstream regulator of PI3K signalling they directed their focus
on genes within this pathway to explain the megalencephaly
phenotype. They subsequently identified one recurrent mutation
in PIK3R2 (c.1117G.A, p.G373R) in three siblings affected with
MPPH arising as a de-novo germline mosaic in one parent. The
same variant was identified in a further 10 cases with MPPH.
By reducing the stringency of their standard exome analysis
pipeline so that variants with just two or more mutant reads were
considered, the authors identified several different de-novo muta-
tions in PIK3CA as causes of MCAP. These variants, which include
c.2176G.A p.E726K, have mutant allele frequencies ranging
from 2–50% in their exome data and were missed by their
standard exome analysis pipeline which used the default hard
filtering parameters [5].
We exome-sequenced three sporadic MEG cases and searched
for genes with recurrent de-novo mutations. Due to the genetic
heterogeneity of these MEG cases, and the involvement of post-
zygotic mutations with low mutant allele frequencies, our standard
analysis failed to identify any genes with recurrent de-novo
mutations. We therefore optimised our exome analysis pipeline
for the detection of variants with low mutant allele frequencies and
reanalysed our MEG exomes. This revised analysis identified the
underlying disease mutations in all three of our MEG cases. We
describe here the phenotypes and causal mutations of our patients,
their correspondence with the newly defined MCAP and MPPH
syndromes, and an evaluation of the methods used to optimise our
pipeline for the identification of variants with low mutant allele
frequencies. These findings should inform optimisation analysis
pipelines for detecting low level mosaic causal variants in next
generation sequencing data for these and other diseases.
Materials and Methods
Cases and Phenotypes
Three MEG cases were selected for exome sequencing whose
phenotypes according to proposed diagnostic criteria [6] are listed
in Table 1. All three cases show characteristic MRI scans with
varying degrees of cortical dysplasia. Two patients have arrhyth-
mias very characteristic of MEG. Patient 1 has macrocephaly
(+8SD), a broad forehead, a wide flat nasal bridge, downslanting
palpebral fissures, a philtral heamangioma, lax abdominal wall,
truncal hypotonia and small joint hypermobility. She also has
widespread keratosis pilaris especially on her limbs and deep
palmar and plantar creasing. Ulnar deviation at the wrists was
noted, very much like that seen in Costello syndrome. Hydro-
cephalus requiring a third ventriculostomy and shunt insertion
developed with time and on the last genetics assessment, aged 5
years, moderate/severe developmental delay in all areas was
apparent. She has had a normal array-CGH and is normal for
PTEN (data not shown). Patient 2 had macrocephaly (+4SD),
characteristic facies with a broad forehead hypertelorism and a
marked philtral haemangioma. He also had widespread cutis
marmorata and 2.3 toe syndactyly. A pernicious atrial arrhythmia
developed at 2 months of age for which treatment was unsuccessful
and the patient died. No developmental information is therefore
available on this case. A karyotype showed a normal male
complement. Patient 3 has macrocephaly (+6SD which had been
noted initially antenatally on the 20 week scan), characteristic
facies with a philtral haemangioma and widespread cutis
marmorata in the newborn period. He was last reviewed by
genetics at 2 years of age at which point he had moderate motor
delay, but borderline normal cognitive development. He was
noted to have keratosis pilaris of all four limbs and deep palmer
and planter creases. His general health had been good other than
one renal tract infection at 5 months of age that had resulted in
some renal scarring. Array-CGH was normal.
Table 1. Causal genotype and phenotypes in three cases with megalencephaly.
Causal mutation Patient 1 Patient 2 Patient 3
PIK3CA p.E726K PIK3CA p.E726K PIK3R2 p.G373R
Major phenotypic criteria (requires one)
Macrocephaly +++ ++ ++
Capillary malformation +++ +++ ++
Overgrowth/asymmetry +++ +
Ventriculomegaly +++ +
Cavum septum pellucidum or cavum vergae
Cerebellar tonsillar herniation + Not tested
Cerebral and/or cerebellar asymmetry ++ Not tested +
Minor phenotypic criteria (requires two)
Developmental delay ++ Not tested +
Midline facial capillary malformation ++ + ++
Neonatal hypotonia +++ + +
Syndactyly or polydactyly +
Frontal bossing + + +
Connective tissue abnormality + +
Hydrocephalus +
Severity of phenotype indicated by number of +’s.
Blank cells represent absence of phenotype.
doi:10.1371/journal.pone.0086940.t001
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Exome Sequencing and Standard Analysis Pipeline
Genomic DNA from the three MEG patients was extracted
from whole blood and their exomes were enriched and captured
using Agilent SureSelect kit (Human All Exon 50 Mb) and
sequenced using an Illumina HiSeq 2000 at the Wellcome Trust
Centre for Human Genetics at Oxford. Approximately 6 gigabases
of 100bp paired-end read sequences were generated per sample.
The Novoalign software (version 2.08.02, Novocraft Technologies,
Selangor, Malaysia) was used to align this sequence data to build
36 (hg18) of the reference human genome. Duplicate reads, due to
PCR clonality or optical duplicates, reads mapping to more than
one location, and reads failing platform or vendor quality checks
were removed. Coverage statistics were calculated using the
BedTools software.
In the standard analysis pipeline, variants were called on a
single sample basis using a two-step procedure in Samtools version
0.1.18 [7]. In the first step mpileup is used to compute the
likelihood of data given each possible genotype. During this
process probabilistic realignment is used to compute the base
alignment quality (BAQ), which represents the probability that a
read base is mis-aligned. In general, this increases sensitivity and
decreases specificity and helps to exclude false positives due to
alignment artifacts caused by nearby indels. In the last step, the
view command of bcftools is used to call variants when the variant
calling threshold (P) is below 0.5, P(ref|D,F) and where ref is the
reference allele, D are data and F is the prior allele frequency
spectrum (AFS). The AFS describes the distribution of SNP sites
based on the number of chromosomes that carry a given allele in a
sample [8] and is computed using an iterative EM algorithm. In
the standard analysis pipeline the ‘full’ AFS model is used to
compute the probability of seeing k alternative (non-reference)
alleles from M chromosomes tested.
Alternative Exome Pipelines
We explored several non-standard pipelines to determine which
provides greater power to detect variants with low mutant allele
frequencies which may result from post zygotic mutations. These
alternative methods are outlined as follows:
1. Multi-sample calling of all three MEG cases simultaneously
using Samtools mpileup. By combining evidence across
samples this method can identify variants which have
insufficient data in individual samples due to low coverage. It
is also possible that some false positive variants will be excluded
when multiple samples are used. However, the power to detect
singleton SNPs is diminished when multiple samples are
considered.
2. Varying the initial AFS using bcftools. If the initial AFS is far
from the solution EM iteration may require more cycles and,
more importantly, may converge to a local, sub-optima,
solution [7]. The final SNP calling outcomes may therefore
be sensitive to the choice of the initial AFS. Li (2010 http://
lh3lh3.users.sourceforge.net/download/multigeno.pdf) de-
scribes two alternative initial AFS conditions, ‘cond2’ and
‘flat’, derived from the infinite site Wright-Fisher model. These
alternatives compute the probability of seeing k non-reference
alleles from two chromosomes (cond2) or from one chromo-
some (flat) which gives a flat initial AFS. We therefore recalled
variants using the cond2 and flat initial AFS settings.
3. Reduced variant calling threshold using bcftools. In the
standard pipeline, variants are called when the variant
threshold is less than 0.5. Using bcftools (view option –p), we
relaxed this threshold to 0.75 and 1.
4. Elevation of the mutation rate using bcftools. In the standard
pipeline, the scaled mutation rate is 0.001. We used bcftools
(view option –t) to increase this to 0.01 and 0.1.
Simulation of Sequence Data with a Range of Mutant
Allele Frequencies
To further explore the sensitivity of these methods to detect
variants with low mutant allele frequencies we simulated 100bp
paired end sequence data with total read depth ranging from 4 to
100 and mutant read frequencies ranging from 1% to 50%. All
reads were simulated to be mapped in the correct orientation and
within insert size, to be evenly distributed on the positive and
negative strand, to have mapping qualities of Phred 60, and to
have base qualities of Phred 30. Reads with the reference allele
were identical to the reference (CIGAR = 100 M, MD:Z:100)
while reads with the alternative allele had one mismatch that was
located in the middle of the read (CIGAR = 100 M,
MD:Z:50G49). The sensitivity of each method of exome analysis
was determined by recording the minimum alternate allele
frequency at which the variant was detected and Wilcoxon signed
rank tests were used to compare the minimum alternate allele
frequency between methods.
Variant Filtering and Comparison between Patients
Following variant calling, vcfutils which is part of VCFTools [9]
and custom scripts were used to select variants with good
supporting evidence and to stratify them into two tiers according
to a range of filtering criteria. In the first tier, vcfutils was used to
select variants with base call accuracy $90% (Phred $10), total
read depth $4, alternative read depth $2, strand bias P$0.0001,
base quality bias P$1e-100, tail bias P$0.0001, and HWE
P$0.0001. In addition, custom scripts were used to exclude
variants located within or adjacent to repetitive DNA including
homopolymers $5 bp. In the second more stringent tier variants
were required to have $3 reads with the alternative allele, $1
read with the alternative allele on each strand, strand bias P$0.01,
base quality bias P$0.01, tail bias P$0.01, mapping quality bias
P$0.01, and excluding genes with excessive numbers of patho-
genic mutations due to their presence within highly polymorphic
regions of the genome, assembly misalignment, or errors in the
reference genome [10].
Novel variants were identified by using Annovar [11] filtering
against public databases (dbSNP129, dbSNP132, 1000 genomes
phase 1 July 2010 release, and European American exomes from
the NHLBI Exome Sequencing Project) and an in-house database
(n = 100 exomes) of known variants. To generate a list of candidate
genes, the novel variants in each patient were compared to identify
genes which contain novel variants in two or more patients which
is a common strategy of exome analysis.
Mutation Validation by Sanger Sequencing and
Pyrosequencing
Sanger sequencing of PCR amplicons from whole blood-
genomic DNA in the probands and two of three unaffected pairs
of parents was used to confirm the presence of variants identified in
silico by exome sequencing and to determine their de-novo status.
For the PIK3CA variant (c.2176G.A, p.E726K) pyrosequencing
was used to determine the level of mosaicism in whole blood-
genomic DNA samples from the probands and their parents by
calculating the average mutant allele frequency from two
estimates. Although the level of PIK3CA mosaicism is higher in
skin fibroblasts and saliva blood was used since saliva and skin
fibroblasts were unavailable.
Exome Sequencing of Megalencephaly Syndromes
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Whole blood-genomic DNA samples from the two probands
and their parents were amplified using primers 59-biotin-
TTGCACGATTCTTTTAGATCTGAG-39 (forward) and 59-
TCCAAATCCTAATCTGCTTGATTC-39 (reverse) and se-
quenced with the primer 59-TCACACACCTTTTGTGTT-39
(reverse orientation). Pyrosequencing reactions were performed
according to the manufacturer’s instructions using the PSQ 96
single nucleotide polymorphism (SNP) Reagent Kit (Biotage),
which contained the enzyme and substrate mixture and nucleo-
tides. Two independent estimates were made for each case.
Results
The coverage statistics show that the mean depth per sample
ranged from 46 to 52 reads and that 85 to 87% of the Gencode
defined target bases were covered by 10 or more reads. Full
coverage information is available in Supplementary Table S1.
Identification of Causal Variants in PIK3CA and PIK3R2
We examined exome data from three MEG cases for the
mutations in AKT3, PIK3R2, and PIK3CA which had been
identified as causal [2]. All methods used correctly identified the
causal variant in patient 1, who is heterozygous for the PIK3CA
c.2176G.A, p.E726K variant, and in patient 3 who is heterozy-
gous for the PIK3R2 c.1117G.A, p.G373R variant (Table 2). In
patients 1 and 3, the alternative allele accounted for a large
proportion of the total reads, between 42% (15/36) and 48% (13/
27), which enabled a high base call accuracy (Phred 155–185) and
confident inference of the heterozygous genotype (Phred 99).
In patient 2, the causal allele (PIK3CA c.2176G.A, p.E726K)
was present at a much lower read frequency, accounting for just
11% (4/36) of the total reads. As a result the default pipeline
determined that patient 2 was homozygous for the reference G
allele despite the genotypic Phred scaled likelihoods identifying the
heterozygous genotype as the most likely and the reference
homozygous genotype having a low probability (P = 0.063,
Phred = 12). The correct heterozygous genotype for this variant
was identified only when the flat and cond2 AFS settings were
used, when the scaled mutation rate was $0.1, when the variant
threshold is set to 1, or when the samples were analysed together.
The strongest evidence for the variant was obtained when the
initial AFS was set to flat which gave a base call accuracy of 94.1%
(Phred = 12.3) and a genotype quality of 96.8% (Phred = 15)
(Table 2). The cond2 model gave similar but slightly less
significant results. Although the variant was also called when the
mutation rate and variant threshold were substantially increased,
the resulting base call accuracies of 65.1% (Phred = 4.57) and
1.6% (Phred = 0.0684) respectively, are below our variant filtering
threshold of 90% (Phred$10) so they would normally be excluded
from the results.
To explore the sensitivity of the multi-sample method for
identifying variants with low alternate allele frequencies, we
repeated this analysis using two copies of patient 2, which have
mutant allele frequencies of 11% for the PIK3CA variant
(c.2176G.A, p.E726K), and patient 3 which has no evidence
for this variant. This analysis failed to identify the variant which
demonstrates that, in these data, multi-sample calling can only
detect low frequency variants when at least two of the samples
being tested have the same variant and it has a high alternate allele
frequency in at least one of these samples.
Confirmation of the Causal Variants and their
Correspondence with MCAP and MPPH
The presence of the causal variants in all three of our MEG
cases was confirmed by Sanger sequencing. Sanger sequencing
was also used to determine that the PIK3CA variant (c.2176G.A,
p.E726K) in patients 1 and 2 is de novo. We could not determine
the de novo status of the PIK3R2 variant (c.1117G.A, p.G373R) in
patient 3 since parental DNA was unavailable. In patients 1 and 2,
the frequency of the mutant allele was estimated to be 20 and 18%
respectively using pyrosequencing (Table 2).
The PIK3R2 variant in patient 3 has previously been associated
with the MPPH phenotype which resembles MCAP but lacks
vascular malformations and syndactyly [2]. The phenotypes
defined for this patient (Table 1) shows an absence of syndactyly,
but there is evidence for capillary malformations which contradict
one of the phenotypic characteristics of MPPH. In addition this
Table 2. Characteristics of causal variants in PIK3CA and PIK3R2.
Feature Patient 1 Patient 2 Patient 3
Causal mutation PIK3CA p.E726K PIK3CA p.E726K PIK3R2 p.G373R
Frequency of mutant allele by pyrosequencing 20% 18% NA
Total number of reads 36 36 27
Frequency of reference allele reads 58.3% (8+,132) 88.9% (13+,192) 51.9% (6+,82)
Frequency of mutant allele reads 41.7% (4+,112) 11.1% (1+,32) 48.1% (9+,42)
Mapping quality 60 60 60
Phred scaled genotype likelihoods (00/01/11) 185,0,236 12,0,233 179,0,197
Default (Phred base accuracy, genotype confidence) 155, 99 Not identified 149, 99
Allele frequency spectrum=Flat 185, 99 12.3, 15 179, 99
Allele frequency spectrum=Cond2 183, 99 10.6, 14 177, 99
Mutation rate = 0.01 165, 99 Not identified 159, 99
Mutation rate = 0.1 176, 99 4.57, 12 170, 99
Variant threshold = 0.75 155, 99 Not identified 149, 99
Variant threshold = 1.0 155, 99 0.0684, 7 149, 99
Multi-sample default 157, 99 157, 10 139, 99
doi:10.1371/journal.pone.0086940.t002
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patient also has significant bifrontal band heterotopia which is
inconsistent with MPPH. A close relationship between these forms
of MEG has been noted including a case with strongly overlapping
phenotypes [2]. As more cases of MEG are reported it is likely that
further phenotypic overlaps will become apparent.
Of 24 cases with PIK3CA mutations, 23 were diagnosed with
MCAP [2]. Accordingly, patients 1 and 2 would be classified as
MCAP rather than MPPH due to their de-novo mutations in
PIK3CA. The phenotypes of patients 1 and 2 are consistent with
the published definition of MCAP [1] although the phenotypic
data for patient 2 is limited due to the patient’s short lifespan.
Exome Wide Evaluation of Our Standard and Alternative
Exome Analysis Pipelines
To determine the effects of the alternative variant calling
methods on the number of variants identified and their data
quality we applied these methods to the three MEG exomes and
filtered the variants using the moderate (tier 1) and stringent (tier 2)
quality criteria. We then identified variants that were ‘unique’ to
each of the alternative methods in comparison with the default
analysis. These unique variants were characterized by calculating
various indicators of sequence and data quality such as the average
base call accuracy, the proportion of variants with significant
biases (strand, base quality, tail, or mapping quality bias P#0.05),
and the proportion of variants which occur in genes with excessive
numbers of pathogenic mutations. Finally, novel variants were
identified and compared between samples to identify genes which
contain novel variants in two or more samples.
In terms of the average number of variants in tier 1, our default
analysis was the most conservative (n = 22,275 variants) and the
multi-sample method was the most liberal (n = 23,934) (Table 3).
Although the multi-sample method identified the most variants it
was also the only method which did not identify all of the variants
from the default analyses. On average, 378 of the default variants
were not called by the multi-sample approach. This group of
variants has the highest proportion of variants located in genes
with excessive mutation rates (33.6% versus 13.4%) and variants
with significant biases (47.4% versus 11.5%) which suggests that
many of them are likely to be false positives (Supplementary Table
S2). When the variant threshold was altered no additional variants
were identified in comparison to the default analysis. As a result
the variant threshold options were excluded from further analyses.
In comparison to the default analysis, the unique variants
identified by the AFS options (flat and cond2), mutation rates (0.01
and 0.1), and multi-sample analysis have significantly higher
proportions of variants with only two alternate alleles and variants
with alternative alleles on only one strand (Supplementary table
S2). In addition, these unique variants have lower base call
accuracies and fewer reads (total and alternative) compared with
the default analysis which suggests that many of them may be false
positives. However, the causal variant in PIK3CA with low copy
number is amongst these unique variants so hard filtering must be
approached with caution when low copy number mosaic
mutations are considered.
When tier 1 filtering is used to identify genes with novel variants
in two or more patients, the causal gene for MCAP (PIK3CA),
shared by patients 1 and 2, is not identified by the default analysis
but is correctly called among 50 genes identified by the multi-
sample method and 143 and 169 genes identified by the AFS
cond2 and AFS flat models respectively (Table 4). Ten of these
genes have been identified as having abnormally high mutation
rates [10] so are unlikely to contain causal variation but a
significant number of genes remain when these are excluded.
When these comparisons were repeated using the more stringent
tier 2 filtering, the default analysis identified five genes (DIP2C,
TP53BP1, PLEKHG5, BAHCC1, and KIAA1324) with novel
variants in two patients (Table 4) but failed to identify the PIK3CA
mutations shared by patients 1 and 2. In contrast, the alternative
AFS methods (flat and cond2) identified one additional gene with
novel variants in two patients which was PIK3CA. The multi-
sample method also identified these genes as being present in
twopatients in addition to one other gene in two patients (TTLL5)
and two other genes (AURKC and NPEPL1) in three patients.
Table 3. Mean number of variants identified.
Method of exome analysis Mean number of variants Mean number of novel variants
Tier 1 Tier 2 Tier 1 Tier 2
Default 22275 16223 191 103
Allele frequency spectrum=Flat 23558 16267 697 109
Allele frequency spectrum=Cond2 23460 16265 638 108
Mutation rate = 0.01 22686 16243 278 104
Mutation rate = 0.1 23134 16257 467 106
Variant threshold = 0.75 22275 16223 191 103
Variant threshold = 1.0 22275 16220 191 103
Multi-sample default 23934 15928 205 99
doi:10.1371/journal.pone.0086940.t003
Table 4. Number of genes with novel variants in x or more
samples.
Moderate QC, tier 1 Stringent QC, tier 2
Number of samples $1 $2 $3 $1 $2 $3
Default 536 12 1 297 5 0
AFS Flat 1768 169 12 312 6 0
AFS Cond2 1650 143 7 310 6 0
Mutation rate 0.01 771 26 1 301 5 0
Mutation rate 0.1 1244 87 2 307 5 0
Multi-sample default 527 50 15 279 9 2
doi:10.1371/journal.pone.0086940.t004
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The variants in DIP2C were excluded after Sanger sequencing
confirmed their presence in parents who have normal phenotypes.
The other genes identified by our default and alternative analyses
were also ruled out on the basis that they involved at least one
synonymous variant or one variant that was predicted to be benign
(Supplementary Table S3).
When focusing on the variants in tier 2 which pass stringent
QC, the methods used for variant calling are very similar in terms
of the average numbers of variants identified which is 16203 per
sample (Table 3). However, only three of these methods (AFS flat
and cond2 and multi-sample) identified the causal PIK3CA variant
when it was present at a low mutant allele frequency in patient 2.
Of these methods, the flat AFS model gave the strongest support
for the low frequency PIK3CA variant and fewer candidate genes
with recurrent novel mutations compared with the multi-sample
method. Furthermore, the multi-sample method could only detect
the low frequency PIK3CA variant when the same variant was
present in a second sample with high mutant allele frequency. In
comparison to the default analysis, the flat AFS model identified
an average of 44 additional variants per sample which includes the
causal PIK3CA variant in patient 2 (Supplementary Table S4).
These additional variants have relatively low base call accuracies
(Phred#39) and 84% of them have mutant allele frequencies
#20%. As a result the majority of these variants form a cluster
which partly overlaps with the lowest level mutations that are
called by the default analysis (Figure 1 and supplementary Figures
S1 and S2).
Evaluation of Exome Analysis Pipelines Using Simulated
Data
The sensitivity of our standard and alternative exome analysis
pipelines to detect rare variants was further investigated by using
simulated data to determine the minimum mutant allele frequency
that was required for variant identification at total read depths
ranging from 4 to 100. The flat AFS model identified the variant
at mutant allele frequencies that were significantly lower than the
default analysis (figure 2a, Wilcoxon signed rank test
p = 1.8610217, AFS flat average 13% range 10.5–25% versus
default average 16.9% range 13.7–50%). In addition, the base call
accuracies of the AFS flat model were higher than the default
analysis (figure 2b, AFS flat average phred = 12.5 range 3.54–30
versus default average phred = 10.6 range 3.01–26). The only
method which identified the variant at frequencies that were lower
than the flat AFS model was the variant threshold equal to 1.
However, the resulting base call accuracies for this variant
threshold are much lower than the other methods and indicate
that this method may struggle to differentiate between sequencing
errors and real variants (average phred = 0.006, range 0.27–
4.8610216). The sensitivity and base calling accuracy of the
remaining methods (AFS cond2, mutation rates equal to 0.01 and
0.1, and variant threshold equal to 0.75) were intermediate
between the default and AFS flat options (supplementary figure
S3).
In summary, the flat AFS model was determined to have the
greatest power to detect variants with low mutant allele
frequencies in whole exome data from 3 MEG cases and in
simulated sequence data with a range of coverage and mutant
frequencies. We therefore recommend that the flat AFS method is
used in support of a standard pipeline when searching for causal
mutation(s) that could have low levels of mutant reads as a result of
somatic mutation. Since sequencing and alignment errors may also
give rise to low frequency variants we also recommend that the flat
AFS method is used in conjunction with stringent QC procedures.
Figure 1. Variants identified in sample 2 by the full and flat AFS models including the mosaic post zygotic variant in PIK3CA.
doi:10.1371/journal.pone.0086940.g001
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Discussion
Riviere et al [2] identified a striking correlation between MEG
phenotypes and genotype to the extent that 23 out of 24 unrelated
individuals with mutations in PIK3CA were diagnosed with MCAP
and all 14 cases with MPPH, of which two are related, had a
recurrent c1117G.A mutation in PIK3R2 or a mutation in AKT3.
The only exceptions were one individual with an AKT3 mutation
and an overlapping phenotype and one case with a PIK3CA
mutation diagnosed with MPPH. On the basis of this correlation,
patient 3 from our study with a PIK3R2 mutation is expected to
have MPPH. However, according to the phenotype of this patient
and in particular the marked bifrontal band heterotopia (Table 1)
this patient could be diagnosed with MCAP. Furthermore,
syndactyly/polydactyly, which is a feature of MCAP, is not
evident in patient 1 who has a PIK3CA mutation. Our findings
suggest that there may be a greater degree of overlap between
these phenotypic classifications than the available studies suggest.
The receptor tyrosine kinase (RTK)-PI3K-AKT pathway is
known to promote growth and contain additional disease related
somatic mutations [12]. Other sporadic disorders caused by
somatic mosaic events rather than germline mutations include
activating mutations of AKT1 associated with Proteus syndrome
[4] and gain of function mutations in PIK3CA causing macro-
dactyly [13]. Recently a syndrome comprising congenital lipoma-
tous overgrowth, vascular malformations, epidermal nevi, and
skeletal/spinal abnormalities (CLOVES syndrome) has been
found to involve postzygotic mutations and identified somatic
mosaic mutations in PIK3CA in affected individuals [14]. Exome
sequencing revealed missense PIK3CA mutations in six patients
with mutant allele frequencies that ranged 3% to 30%. To detect
low frequency variants and discount false positive sequencing
errors, the authors ranked variants according to the number of
reads with the mutant allele hence a variant present in 3 of 50
reads (6%) was ranked higher than a variant present in one of 5
reads (20%). Similarly Riviere et al [2], after failing to identify
causal mutations in some cases through their standard pipeline
undertook a second analysis to examine all variants that did not
meet their initial hard filtering criteria. They examined 6 case
exomes and 174 controls and found many in-silico variants in
PIK3CA which consisted of 1 or 2 reads with mutant alleles but
only 12 variants that were supported by 3 or more mutant reads of
which a significantly higher proportion were in the MCAP
phenotype cohort. Using a threshold of four variant reads they
identified candidate mosaic variants in five of the six cases and
none in controls (confirmed as present by Sanger sequencing).
This suggests that variants supported by one to three reads are
sequencing artefacts although this is dependent on the depth of
coverage. Furthermore, identification of low frequency variants
using a threshold of four variant reads may be less practical when
less is known about the causative pathways and many genes
require screening.
We have found that the most effective strategy for identifying
low level mutations, as applied to real and simulated sequence
data, is to use an initial allele frequency spectrum (AFS) with a flat
distribution for variant calling. In the observed whole exome data,
the flat AFS provided the strongest support for a low level mosaic
mutation which causes MCAP and was not detected by a standard
method of analysis. Although a multi-sample method, which uses
simultaneous assessment of multiple samples, also identified this
low level mutation our results demonstrate that this is dependent
on the same variant being present at a high mutation frequency in
at least one other sample. In addition our results indicate that,
after stringent filtering, a larger number of apparently recurrent
variants remained when using the multi-sample approach which
could impede identification of causal variation in other samples.
We also detected the low level mutation using substantial
alteration of the variant threshold or the scaled mutation rate.
However, both of these methods gave poor base calling accuracy
and objective selection of appropriate thresholds is more
Figure 2. Evaluation of select methods of exome analysis using simulated data. (A) Minimum mutant allele frequencies for identification of
a simulated variant at total read depths ranging from 4 to 100. (B) Base call accuracies of a simulated variant identified at the minimum mutant allele
frequency. As total depth increases, the minimum percentage of the alternative or mutant allele that is required to identify the variant decreases until
a total depth is reached at which an additional read with the alternate allele is required to detect the variant. At these total read depths, the addition
of an alternate read causes the mutant allele frequency and the base call accuracy to increase. Consequently, the plots of minimum alternate allele
percentage (A) and corresponding base call accuracies (B) are composed of a series of spikes at which points an additional alternate read was
required to identify the variant.
doi:10.1371/journal.pone.0086940.g002
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challenging than adopting the flat AFS model when searching for
low frequency mutations. These findings were replicated and
expanded by the analysis of simulated data which showed that the
flat AFS model identified variants at significantly lower mutation
frequencies and higher base call accuracies than the default
method (AFS full) at a range of sequencing depths.
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